Blue Cap Ag · XETR:B7E
Blue Cap — Deutsches Eigenkapitalforum 2022
29 slides from Blue Cap's conference presentation, Nov 29, 2022
Slide 1: Investor Presentation – Deutsches Eigenkapitalforum
Investor Presentation Deutsches Eigenkapitalforum Tobias Hoffmann-Becking, CEO 29 November 2022 Blue Cap AG
Slide 2: Agenda
Agenda 01_ Investment Highlights 02_ Portfolio Performance
Slide 3: 01_ Investment Highlights
Investment 01_ Highlights
Slide 4: Unique opportunity to invest in German SME companies
Investment Highlights Unique opportunity to invest in German SME companies 01_ Proven and unique business model 02_ Diversified portfolio with high value potential 03_ Track record for value growth 04_ Substantial earnings growth 05_ Solid financial foundation 06_ Attractive dividend yield Blue Cap
Slide 5: Proven and unique business model – Private Equity as public listed entity
01_ Proven and unique business model – Private Equity business model as public listed entity BUY TRANSFORM SELL ▪ Investment situations, among Active development & implementation of ▪ Active sales process: others: individual strategies under independent best-owner approach management: Succession ▪ P
Slide 6: Differentiation to other listed investment companies
01_ Proven and unique business model: Differentiation to other listed investment companies “Best Owner” approach Buy, Buy,Turnaround, Sell Turnaround, Sell ▪ We keep our portfolio companies as long as we are the “Best Owner”, and value creation is still possible with Blue Cap as main shareholder ▪ W
Slide 7: Diversified portfolio with high value potential (1/4)
02_ Diversified portfolio with high value potential (1/4) Portfolio of Net asset value share by segment (*) ▪ 9 companies with headquarters in Germany % ▪ More than 1,300 employees Business ▪ Four major segments represent the value of the group (*) Services 19% Plastics 41% Medical 24% 15% Adhesives
Slide 8: Diversified portfolio with high value potential (2/4) – Plastics
02_ Diversified portfolio with high value potential (2/4) Plastics: 41%* ▪ Manufactures lightweight plastic boards from recycled plastic primarily for the logistic and automotive industry ▪ Equity story: profits from sustainability Invest: 2019 / 100% trends, new applications/markets Revenue: € 59 m
Slide 9: Diversified portfolio with high value potential (3/4) – Adhesives & Coatings, Medical
02_ Diversified portfolio with high value potential (3/4) Adhesives & Coatings: 15%* ▪ Niche supplier of adhesive products for different industries ▪ Equity story: transformation of Invest: 2009 / 100% customer mix, boost international sales Revenue: € 36 mn ▪ Leading international company for self-
Slide 10: Diversified portfolio with high value potential (4/4) – Business Services
02_ Diversified portfolio with high value potential (4/4) Business Services: 19%* ▪ Electronic product and systems distributor with a special focus on value-add through technical consulting and development expertise ▪ Equity story: further develop profitable growth story, Invest: 2021 / 93% Revenue:
Slide 11: Track record for value growth – high return on invested equity capital
03_ Track record for value growth – high return on invested equity capital targeted Production Technology Metal Technology Medical Technology Medical Technology Adhesive Technology ▪ Investment: 2011 ▪ Investment: 2016 ▪ Investment: 2014 ▪ Investment: 2012 ▪ Investment: 2009 ▪ Exit: 2022 ▪ Exit: 202
Slide 12: Track record for value growth – indicative high value per share
03_ Track record for value growth – diversified portfolio with indicative high value per share Net Asset Value as of June 30, 2022 EUR mn 168.5 0.7 40.9 155.2 Indic. NAV per share 32.7 € 38.34 25.4 68.8 Plastics Adhesives & Coatings Business Services Medical Net Debt Holding / Indicative Group NAV I
Slide 13: Substantial earnings growth: 9M 2022 figures
04_ Substantial earnings growth: 9M 2022 figures confirm positive effects from transformation Growth Rates We have built a strong group during the last 3 years 2019-2022 9M 2019 – 9M 2022 ▪ Since end of 2019 strong growth in all key metrics despite Covid-19 impacts Revenue +63% ▪ Risk significantly
Slide 14: Solid financial foundation – strong equity and leverage ratios
05_ Solid financial foundation – strong equity and leverage ratios Equity and equity ratio Adj. EBITDA and leverage ratio (rS) EUR m and in % of total assets EUR m and in years (rS) Net debt/adj. EBITDA 36 34.4 5 37% 09/22 112.6 34 4.3 32 30 28 4 26 24.6 2021 98.2 37% 24 Target 22 3 < 3.5x 20 17.6 2
Slide 15: Attractive dividend yield
06_ Attractive dividend yield Dividend per share and dividend yield Investors should participate in our success EUR and % 4.0% 4.0% 4.0% 3.7% 3.3% 0.85 Euro per share for FY 2021 1.00 1.00 ▪ Increase of the base dividend by 13% 0.85 ▪ A special dividend was not considered as no significant 0.25 hold
Slide 16: Portfolio Performance
bh BLUE CAP Portfolio = Performance
Slide 17: Current developments in our portfolio – Plastics
Current developments in our portfolio Plastics Plastics Market trends Financial development 9M 2022 Key topics for 2022/23 Short-term ▪ Benefits from large logistics order ▪ Substantial reduction of project business, ▪ Pressure on margin due to postponement of larger orders ▪ Reduced availability of
Slide 18: Current developments in our portfolio – Adhesives & Coatings
Current developments in our portfolio Adhesives & Coatings Adhesives & Market trends Financial development 9M 2022 Key topics for 2022/23 Coatings Short-term ▪ Production and sales increased in Q3 ▪ Implementing adjusted business model, focus ▪ Ongoing restructuring effects on on production without
Slide 19: Current developments in our portfolio – Business Services
Current developments in our portfolio Business Services Business Services Market trends Financial development 9M 2022 Key topics for 2022/23 Short-term ▪ Continued strong order entry and backlog ▪ CEO hired (Oct/22) to build strong group ▪ Eased supply chains increase revenue ▪ Definition of new str
Slide 20: Current developments in our portfolio – Medical
Current developments in our portfolio Medical Medical Market trends Financial development 9M 2022 Key topics for 2022/23 Short-term ▪ Stable revenue until Q3 ▪ Continued investments in R&D, sales and ▪ 2nd location Taiwan up and running processes ▪ Significant team expansion for next growth ▪ Implem
Slide 21: Outlook
Outlook Continued focus on operating performance: Confirmation of guidance 2022 Inflation, energy crisis, supply chain issues and upcoming recession shift focus to operational performance ▪ Confirmation of guidance 2022: Sales of EUR 335-350 mn and EBITDA (adj.) margin of 8-9% Price management, pass
Slide 22: Questions and Answers
5 BLUE CAP oa and Answers
Slide 23: Thank you for your attention!
Thank you for your attention!
Slide 24: Contact
Contact Tobias Hoffmann-Becking CEO, M&A / Capital Markets hoffmann-becking@blue-cap.de +49 89 288909-10 Blue Cap AG Ludwigstraße 11 office@blue-cap.de 80539 München www.blue-cap.de
Slide 25: Appendix
Appendix
Slide 26: Experienced management team with complementary skills
Experienced management team with complementary skills Tobias Hoffmann-Becking Henning Eschweiler Matthias Kosch Chief Executive Officer Chief Operating Officer Chief Financial Officer Main Responsibilities Main Responsibilities Main Responsibilities ▪ M&A Business ▪ Portfolio Management ▪ Finance an
Slide 27: Blue Cap on the stock market
Blue Cap on the stock market Reference Data Positive Recommendations by Analysts ▪ ISIN/WKN: DE 00A0JM2M1 / A0JM2M ▪ Ticker: B7E, B7E.DE (Reuters), B7E:GR (Bloomberg) Analyst Date Rating Target Price ▪ Share Capital: 4,396,290.00 Euro / 4,396,290 pcs M.M. Warburg 03.11.2022 Buy 40.00 € ▪ Market Segm
Slide 28: Financial calendar and contact details
Financial calendar and contact details Date Event Location 28-30 November 2022 Deutsches Eigenkapitalforum Frankfurt / Main Lisa Marie Schraml Stay informed about Investor Relations & Corporate Communications the latest news and developments and lschraml@blue-cap.de receive our press +49 89 288909-2
Slide 29: Disclaimer
Disclaimer By accessing this document, you acknowledge the restrictions on use set out Insofar as the information contained in this document is based on statements herein. The information contained in this document regarding Blue Cap AG made by third parties, we would like to point out that no warra